THE FUTURE OF DRUG RESEARCH AND MEDICAL DIAGNOSTICS

WEB SUMMIT 2015

EVOLUTION OF COMPUTER TECHNOLOGY

3

EVOLUTION OF COMPUTER TECHNOLOGY

EVOLUTION OF DRUG DISCOVERY TECHNOLOGY

5

EVOLUTION OF DRUG DISCOVERY TECHNOLOGY

THE PROBLEM

THE PROBLEM

  Well plate technology has not changed in over 50 years

  This 50 year-old technology is inefficient and comes with high capital costs

  Complicated workflows

  Need large testing volumes (loss of reagents)

  Unstable (greater room for errors)

7

CURRENT SOLUTIONS ARE INADEQUATE

CURRENT SOLUTIONS ARE INADEQUATE

  Costly Capex (smaller companies cannot afford the current technology)

  Not scalable

  Cannot handle high testing volumes

  High margin for errors

Competitors believe these obstacles are just part of doing business. Neofluidics knows better, and we deliver on that knowledge by providing more efficient workflows through engineering-driven technology.

9

THE NEOFLUIDICS SOLUTION

Reduced sample volumes

= 99% cost savings!

Our lab-on-a-chip technology is in position to change the future of the field of drug discovery.

THE NEOFLUIDICS SOLUTION

No Capex (affordable for all companies,

large and small)

Compatibility with existing equipment

Error-free pipetting control

Enhanced quality of

testing

Ease of dilution On-site testing Fast results

A NEW PLATFORM FOR SCREENING TECHNOLOGY

A NEW PLATFORM FOR SCREENING TECHNOLOGY

Neofluidics products bring unprecedented efficiency to many different types of screening workflows by offering the following benefits:

  Drastically reduces the volume needed to test compounds, not only allowing more tests to be run with rare compounds, such as with those from plant-derived sources that are available in extremely limited quantities, but also reducing reagent costs by up to 99%.

  Does not require additional Capex, which enables smaller companies with limited budgets to undertake large-scale drug screening campaigns.

  The simplicity and small footprint of the technology facilitates point of care diagnostics, increasing sensitivity of typical ELISA based screening.

13

A NEW PLATFORM FOR SCREENING TECHNOLOGY

  Can screen small animal models (such as C.elegans and Zebrafish) in a high throughput fashion.

  Can perform single-cell analysis with a series of microfluidic trapping chambers designed to capture single cells from a larger initial population.

  Can facilitate cell culture and tissue organ modeling to test drug toxicity.

14

Zebrafish

THE MARKET

THE MARKET

New market research1 on the High Throughput Screening Market by Technology, Applications, and End Users:

  R&D costs to discover a single drug have risen to $2.9-9 billion USD.2

  In the past 50 years, the money spent on drug discovery has increased by 674%.   The primary screening segment of

drug discovery is poised to grow at the highest compound annual growth rates in the industry.

$13.7

2013CurrentglobalHTSscreeningmarket

Billion

$19.6 Billion

2018(ProjectedCAGRof7.4%)

16

THE MARKET

17

1 www.marketsandmarkets.com 2

Diagnosing the decline in pharmaceutical R&D efficiency, Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington, Nature Reviews Drug Discovery 11, 191-200 (March 2012)

THE NEOFLUIDICS STORY

Delivering on technology.  

Neofluidics was born out of a doctoral thesis and has since disrupted a microfluidics product category that hasn’t changed in fifty years.  

We challenge prevailing assumptions in fluid mechanics regarding complicated workflows, pipetting errors, and high screening costs.  

Neofluidics develops next-generation tools and technology not only for the bioscience sector, but also in the military and petroleum sectors for enhanced microfluidics.

 

Our engineering-driven products add unprecedented convenience and efficiency to workflows, significantly reducing the costs of testing, culture, measurement, and analysis.

18

MARKET OPPORTUNITY

MARKET OPPORTUNITY

Audiences

Lab Screening Technicians

Single-Cell Genomics and Cancer Research

Scientists

Point-of-Care Diagnostics Providers

Pharmaceutical Scientists

  Pharmaceutical Screening

  Drug Screening

  Cosmetic Screening

  Pharmaceutical Research and Development

  Academic Research and Development

  Equine Banned Substance Testing

  Sports Banned Substance Testing

  Protein Solution Viscosity Characterization

20

MARKET OPPORTUNITY

Petroleum Engineers Military

  Drilling Fluid Analysis

  In-line Viscosity Measuring For Hydraulic Fluids and Fuel Condition

Future Target Audiences

21

MARKET OPPORTUNITY

Current Clients

22

HOW NEOFLUIDICS STACKS UP AGAINST THE COMPETITION

RESULTS CHART

24

MILESTONES

MILESTONES

MAY 2014

JUL 2014

AUG 2014

SEP 2014

AUG-NOV 2014

JAN 2015

MAY 2015

AUG 2015

MAR-SEP

2015

Oct 2015

DEC 2013

Neofluidics commercial feasibility  through

NSF I-Corps

Winners of the Texas Techcelerator

incubator competition

Raised 200k from angel investors

Acquired exclusive IP

license from Texas Tech University

Set-up a clean lab for device

and application testing

Prototype R&D

completed

Neoplate product launch

Optimization of the Neoplate

based on feedback

Two proprietary patents held,

with 4 different product lines

Neoplate Prototype launch for field-testing to 30 customers

Proprietary patent for the company IP filed

and Neoplate prototype manufacturing initiated

DEC 2014 Application 

testing  started

26

MEET OUR TEAM

MEET OUR TEAM

Dr. Deepak Solomon

Chief Product Engineer

Dr. Nilesh Gupta

Chief Scientific Officer

Dr. Kevin Crawford

Chief Operating Officer

Charles E. Needham

Chief Marketing Officer

Alpesh Indulkar

Chief Manufacturing Officer

Dr. Rathnam Chagturu

Director of HTS at Stanford Research International (SRI)

Dr. Ali Khadim Hosseini

Professor, MIT

Dr. Barbara Smith

Professor, ASU

28